Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis

Clinical Cardiology

Volumn 37, Issue 6, 2014, Pages 337-342

  Mahaffey, Kenneth W ^a,b   Wojdyla, Daniel M ^a   Pieper, Karen S ^a   Tricoci, Pierluigi ^a   Alexander, John H ^a   Lincoff, A Michael ^c   Brennan, Danielle M ^c   Bhatt, Deepak L ^d   Wallentin, Lars ^e   Harrington, Robert A ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; CLOPIDOGREL; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC STABLE ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; RECURRENCE RISK; RISK FACTOR; HEMORRHAGE; HOSPITALIZATION; ISCHEMIA; MORTALITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGE; HOSPITALIZATION; HUMANS; ISCHEMIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 84902536417     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22255     Document Type: Article

References (11)

1. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012; 60: e44-e164.
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
3. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012; 366: 20-33.
4. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365: 699-708.
5. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003; 108: 399-406.
6. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-1717.
7. Nair VN,. Confidence bands for survival functions with censored data: a comparative study. Technometrics. 1984; 26: 265-275.
8. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304: 1350-1357.
9. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
10. Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS). http://www.clinicaltrials.gov/ct2/show/NCT01225562. Published July 9, 2010. Updated October 21, 2013. Accessed December 5, 2013.
11. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404-1413.